Generic olanzapine: health authority opportunity or nightmare?

Araszkiewicz A A, Szabert K, Godman B, Wladysiuk M, Barbui C, Haycox A

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

Indexing Status
Subject indexing assigned by CRD

MeSH
Antipsychotic Agents; Cost-Benefit Analysis; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Poland; Schizophrenia

AccessionNumber
22009100260

Date bibliographic record published
02/03/2009